Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest update is out from Hangzhou Tigermed Consulting Co., Ltd. Class H ( (HK:3347) ).
Hangzhou Tigermed Consulting Co., Ltd. announced the successful conclusion of its 2025 First Extraordinary General Meeting (EGM) held on September 29, 2025, where all proposed resolutions were passed by shareholder vote. The meeting, chaired by Dr. Ye Xiaoping, adhered to relevant PRC laws and regulations, and was validated by legal advisors, confirming the legitimacy of the proceedings. The EGM saw participation from shareholders holding approximately 50.8950% of the total shares with voting rights, ensuring a significant representation in the decision-making process.
The most recent analyst rating on (HK:3347) stock is a Hold with a HK$46.00 price target. To see the full list of analyst forecasts on Hangzhou Tigermed Consulting Co., Ltd. Class H stock, see the HK:3347 Stock Forecast page.
More about Hangzhou Tigermed Consulting Co., Ltd. Class H
Hangzhou Tigermed Consulting Co., Ltd. is a joint stock company incorporated in the People’s Republic of China, operating in the consulting industry. The company focuses on providing clinical trial services and solutions, primarily serving the pharmaceutical and biotechnology sectors.
YTD Price Performance: 46.17%
Average Trading Volume: 4,160,780
Technical Sentiment Signal: Buy
Current Market Cap: HK$49.54B
See more insights into 3347 stock on TipRanks’ Stock Analysis page.